28 May 2016

Burford’s £200m AIM pitch

07/10/09

Burford Capital, which provides finance to companies that wish to contest commercial causes in the courts, is planning a £200 million float on AIM.

Led by former Barclays and current Marsh & McLennan chairman Sir Peter Middleton, the Guernsey-registered company aims to invest the proceeds of the float well within 18 months in commercial disputes in the US and on international arbitration matters. Operating as an investment company, the Plc funds will be managed by founders Christopher P Bogart and Selvyn Seidel.

The company, whose corporate spiel claims ‘we do not just write cheques… we serve as business partners, consultants and case managers’, believes opportunities for dispute financing tend to be more ‘robust’ following economic downturns and notes that international arbitration cases are currently at an all-time high. Bogart, former executive vice president of media conglomerate Time Warner, says 'third-party commercial dispute finance is a high growth market’ and claims that, as an asset class, it is ‘capable of generating highly attractive returns irrespective of the performance of equity markets’.

Burford has engaged Fox-Pitt Kelton (soon to become part of Aussie bank Macquarie) as nominated adviser and broker, with Execution Limited appointed ‘co-lead manager’. Its shares are expected to be admitted on 16 October.

Tags: AIM, Dividend, Fundraisings, New Issues

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Motif Bio and the ticking timebomb 23/05/16

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double! 19/05/16

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait  16/05/16

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media  12/05/16

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace 11/05/16

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

Elecosoft constructs a strategy for growth  09/05/16

Elecosoft (AIM: ELCO) is a specialist software company serving architects and builders. It used to be a much larger business but sold out of its building materials businesses four years ago to focus on its software arm. The challenge now is to generate some revenue growth and move off a sales plateau which has been in place since then.

More News